Hemoglobin level variability: associations with mortality.

BACKGROUND/OBJECTIVES Awareness of hemoglobin level variability in dialysis patients is increasing, as is interest in its potential implications. In this retrospective, national study of associations between the degree of hemoglobin level variability in the first 6 mo of 2004 and subsequent mortality rates in the following 6 mo, 159,720 hemodialysis patients receiving epoetin therapy were studied. DESIGN, SETTING, PARTICIPANTS, MEASUREMENTS Monthly hemoglobin values were categorized as low (L; < 11 g/dl), intermediate (I; 11 to 12.5 g/dl), and high (H; >12.5 g/dl). Variability groups were classified on the basis of the lowest and highest hemoglobin categories seen during the 6-mo observation period: low-low (L-L), 1.4%; intermediate-intermediate (I-I), 6.0%; high-high (H-H), 2.3%; low-intermediate (L-I), 18.3%; intermediate-high (I-H), 31.7%, and low-high (L-H), 40.2%. RESULTS On multivariate analysis, adjusted hazards ratios for subsequent mortality events were as follows: I-I, 1.0 (reference category); I-H, 1.02 (95% confidence interval [CI] 0.95 to 1.11); H-H, 1.06 (95% CI 0.93 to 1.21); L-H, 1.19 (95% CI 1.10 to 1.28); L-I, 1.44 (95% CI 1.33 to 1.56), and L-L, 2.18 (95% CI 1.93 to 2.45). Persistently and transiently low hemoglobin levels and highly variable hemoglobin levels were associated with increased risk of death; transiently and persistently high hemoglobin levels were not associated with increased risk of death. Bayesian modeling indicated that > or =3 mo with hemoglobin levels <11 g/dl may be associated with of increased risk of death. CONCLUSIONS Number of months with hemoglobin values below the target range, rather than hemoglobin variability itself, may be the primary driver of increased risk of death. Further research is needed to distinguish cause from effect and to understand the underlying mechanisms.

[1]  Ashutosh Kumar Singh,et al.  Anemia of chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[2]  Huiman Barnhart,et al.  Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.

[3]  H. Burger,et al.  Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.

[4]  R. Foley,et al.  Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[5]  S. Greenland,et al.  Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.

[6]  M. Joffe,et al.  Erratum: Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time (Kidney International (2005) 68 (2323-2330)) , 2005 .

[7]  Harold I Feldman,et al.  Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. , 2005, Kidney international.

[8]  S. Fishbane,et al.  Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.

[9]  Eduardo Lacson,et al.  The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. , 2003, Kidney international.

[10]  J. Lazarus,et al.  Effect of variability in anemia management on hemoglobin outcomes in ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  A. Collins,et al.  Hematocrit levels and associated Medicare expenditures. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  B. Pereira,et al.  Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.

[13]  Avid,et al.  THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .

[14]  A. Collins,et al.  Hematocrit levels and hospitalization risks in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[15]  A. Collins,et al.  Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[16]  W. Owen,et al.  Anemia in hemodialysis patients: variables affecting this outcome predictor. , 1997, Journal of the American Society of Nephrology : JASN.

[17]  Bradley P. Carlin,et al.  BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..

[18]  J. Adamson,et al.  NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.